Your first 90 days
Your first 90 days on Mimrylo for polycythemia vera
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Mimrylo is a weekly shot given at home by you or a caregiver, so the first weeks are about learning to mix and inject it. Before the first carton arrives, the hematologist's office usually sends an enrollment form and the insurance plan reviews it. A healthcare provider shows you how to prepare and give the injection before you start. After that come regular blood counts while the dose is adjusted. This page lays out those first 3 months from the FDA label, Takeda's support program and what insurers have published so far.
The Mimrylo label has been updated. The FDA lists a newer label dated November 2, 2026, and this page was written from the August 28, 2026 label. Trial Friend is checking what changed. Your doctor and pharmacist go by the current label.
What has to happen before the first bottle ships
Mimrylo has no REMS, so the first carton waits on an enrollment form, an insurance approval and injection training, not on a pharmacy counter. These are the 7 things in the way, in order.
A pregnancy test, where it applies
The label recommends a pregnancy test before treatment for anyone who can become pregnant, because animal studies showed harm to the unborn baby.
- It advises effective birth control during treatment and for at least 30 days after the last dose.
- Breastfeeding is not advised during treatment or for 30 days after the last dose.FDA label
Training before the first injection
The label says a healthcare provider should show you or your caregiver how to prepare and inject Mimrylo before treatment starts.
- The Patient Information says not to inject yourself or someone else until you have been shown how.
- Each dose is mixed from a powder and a prefilled syringe of liquid before it is injected.FDA label
Free nurse-led injection training
Takeda's enrollment form says Here2Assist gives free injection training to all enrolled Mimrylo patients.
- Visits can be by video or in person on request.
- The form says registered nurses cover injection technique, site rotation, disposal and managing side effects.Here2Assist enrollment form
A full list of medicines and supplements
The Patient Information asks you to tell your healthcare provider about every prescription and over-the-counter medicine, vitamin and herbal supplement.
- The label itself has no section on drug interactions with other medicines.
- In VERIFY, the main study, Mimrylo was added to each person's usual care, which could include phlebotomy, hydroxyurea, interferon or ruxolitinib.FDA label
The enrollment form and original signatures
The hematologist's office faxes the Here2Assist enrollment form to 1-844-269-3038, or enrolls online.
- The prescriber and the patient, or a legal representative, must sign by hand, and stamped signatures are not accepted.
- The form says the prescription on it is valid only if it arrives by fax.Here2Assist enrollment form
The insurance approval
After enrollment, a Nurse Navigator checks your insurance benefits and out-of-pocket costs.
- The Nurse Navigator also tracks any prior authorization or appeal your doctor may need to submit.
- Takeda says Here2Assist does not submit prior authorizations or appeals itself, so the office files them.Here2Assist coverage
Which pharmacy ships it
Takeda lists 2 specialty pharmacies for Mimrylo, Biologics by McKesson and Onco360 Oncology Pharmacy.
- Some doctors' offices can dispense it in the clinic instead of a pharmacy.
- Here2Assist can help identify the specialty pharmacies that can fill the prescription.Here2Assist pharmacies
The days that matter
Counted from the first injection, with blood counts every 2 to 4 weeks while the dose is adjusted, and one carton for each weekly dose up to 54mg. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment form and insurance check
The hematologist's office sends the Here2Assist enrollment form, or you enroll online.
- A Nurse Navigator then calls, texts or emails to welcome you and reviews what your insurance covers.
Pregnancy test, where it applies
The label recommends a pregnancy test before treatment for anyone who can become pregnant.
- Effective birth control is advised from the first dose until at least 30 days after the last one.
Injection training
The label says a healthcare provider should show you or your caregiver how to mix and inject Mimrylo before treatment starts.
- Ask the office who will teach you, and bring the person who may help with injections.
The first carton ships
A Nurse Navigator works with a specialty pharmacy so the prescription is filled and shipped directly to you.
- Where in-office dispensing is available, you may pick it up at your doctor's office instead.
First injection, 19mg
Under the label, the vial of powder is mixed with the liquid in the carton's prefilled syringe, then injected under the skin within 4 hours.
- The sites are the belly at least 2 inches from the navel or the front of the thigh.
- The outer upper arm is only for injections a caregiver gives.
Blood count, and the earliest dose change
The label calls for a complete blood count every 2 to 4 weeks after starting.
- After at least 2 weeks on a dose, the hematologist may raise it one step, for example from 19mg to 28mg.
Next carton
Each carton holds one vial and one syringe of liquid, which is one week's dose up to 54mg.
- Higher weekly doses use 2 vials, so 2 cartons each week.
- The label does not set how many cartons come in each shipment, so confirm the next delivery date with the pharmacy.
Platelets at about 4 weeks
In the main study, platelet counts rose an average of 31% within the first 4 weeks.
- The blood counts every 2 to 4 weeks are how the hematologist sees whether yours have risen.
Platelets usually level off
The label says platelet counts generally plateaued by week 8.
- Blood counts continue every 2 to 4 weeks during dose changes, or as often as the hematologist decides.
Still early by the study's measure
VERIFY judged response between weeks 20 and 32, as no longer qualifying for a phlebotomy.
- Three months in, the hematologist may still be adjusting the dose toward a hematocrit below 45%.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Mimrylo label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated November 2, 2026, read from the FDA's label database today. FDA label
- November 2026
DailyMed's history shows a new version of the Mimrylo listing posted on November 4, 2026. The label text DailyMed served on November 9 still carried the August 2026 revision date, so we could not see what changed.DailyMed history
- August 2026
This first label, revised in August 2026, has no boxed warning, no contraindications and no recent major changes.FDA label
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Once a week, at the dose your hematologist sets
The label's weekly doses run from 9.5mg to 108mg, starting at 19mg.
- Doses above 54mg take 2 injections, and doses above 82mg are split, with the first on day 1 and the second on day 4 or 5.
- The Patient Information says never to give more than 2 injections in a day.FDA label
- Mixing each dose
The label's steps push all the liquid from the prefilled syringe into the vial, then swirl it gently for about 2 minutes, never shaking.
- It sits about 1 minute so the foam settles, and it should look clear and colorless.
- The label says to inject within 4 hours of mixing and throw it away after that.FDA label
- Where to inject
The belly at least 2 inches from the navel, the front of the thigh, or the outer upper arm when a caregiver gives it.
- The label says not to use the same spot twice in a row, or skin that is tender, bruised, red, irritated, hard or broken.FDA label
- Check the strength
Mimrylo comes in 5 strengths, and the Patient Information says to make sure yours matches the prescribed strength.
- The vial caps are color coded, blue for 9.5mg, lime for 19mg, burgundy for 28mg, yellow for 41mg and white for 54mg.FDA label
- If you miss a dose
On once-weekly dosing, the label says to inject the missed dose as soon as you remember.
- If it was more than 4 days late, the next one comes 3 days later, then the usual day resumes.
- On twice-weekly dosing, a dose up to 2 days late is given right away with the next one 3 days later, and a later one is skipped.
- The label says to call your healthcare provider if you are unsure.FDA label
- Storage and disposal
The label says to store Mimrylo at room temperature, 68 to 77 degrees Fahrenheit, in the original carton to protect it from light, and never to freeze it.
- Used needles, syringes and empty vials go into an FDA-cleared sharps container, or a sturdy container the Instructions for Use describe, never household trash.FDA label
- Pregnancy and breastfeeding
Based on animal studies, the label says Mimrylo may harm an unborn baby.
- The Patient Information says to stop taking it and tell your healthcare provider right away if you become pregnant.
- Breastfeeding is not advised during treatment or for 30 days after the last dose.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of bleeding or a blood clot
Mimrylo can raise platelet counts, which the label lists as a warning.
- The label asks patients to contact their healthcare provider for unusual bruising or bleeding, chest pain, shortness of breath, leg pain or swelling, or a sudden severe headache.FDA label
Injection site reactions
In the 32-week placebo-controlled part of VERIFY, these affected 56% on Mimrylo against 33% on placebo.
- Redness, itching, pain and swelling were the most common kinds.
- The label says ice, steroid cream, antihistamines or pain relievers may help, and to call about a severe or lasting reaction.FDA label
Anemia and shortness of breath
Anemia occurred in 16% on Mimrylo against 4.1% on placebo, and shortness of breath in 8% against 1.4%.
- Anemia led to a lower dose in 10% of patients.
- The label tells the hematologist to lower the dose one step for grade 2 or worse anemia.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedWe found no public insurer policy for Mimrylo as of November 9, 2026. A Nurse Navigator explains the plan's prior authorization process and keeps the office and the pharmacy updated. Takeda offers sample letters of medical necessity and appeal, which the office fills in and submits itself.Here2Assist coverage
- The enrollment form was not acceptedThe form needs original signatures from the prescriber and the patient or a legal representative, and stamped signatures are refused. The prescription on the form is valid only if it arrives by fax, at 1-844-269-3038.Here2Assist enrollment form
- The prescription went to the wrong pharmacyTakeda lists Biologics by McKesson (1-800-850-4306) and Onco360 Oncology Pharmacy (1-877-662-6633) for Mimrylo. In-office dispensing is arranged through a specialty distributor or Here2Assist, Option 5.Here2Assist pharmacies
- A copay you cannot payWith commercial insurance, the Takeda Oncology Co-Pay Assistance Program may lower the cost to as little as $0 per prescription. You must be at least 18, live in the United States or a US territory, and meet the program's other terms.MIMRYLO Patient Support
- Medicare, Medicaid, TRICARE or VA coverageThe copay program's terms exclude anyone whose Mimrylo claims can be paid by a state or federal program. Takeda points these patients to Medicare's Extra Help, the Patient Advocate Foundation, the American Cancer Society and CancerCare.Here2Assist financial help
- No insurance, or the plan will not cover itThe Takeda Oncology Patient Assistance Program may provide Mimrylo at no cost to people who meet its financial and coverage criteria. To apply, you first enroll in Here2Assist and then submit a separate application.Here2Assist financial help
- A gap in commercial coverage after startingThe Bridge Program offers Mimrylo at no cost for up to 2 months during a temporary gap, such as a job loss. It is only for people already taking Mimrylo whose coverage came from a commercial plan.Here2Assist
Checked November 9, 2026
On November 9, 2026 we searched public policies from Express Scripts, FEP Blue, Aetna, Cigna and others and found no Mimrylo criteria. The FDA approved Mimrylo on August 28, 2026, a little over 2 months before that search. Until plans publish their own rules, Takeda's Nurse Navigators can explain what a particular plan asks for after the benefits check. Here2Assist coverage
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A Nurse Navigator who welcomes you, ships a Welcome Kit, checks your insurance benefits and out-of-pocket costs, and tracks any prior authorization or appeal
- Free one-on-one injection training from a registered nurse for you or a care partner, by video or in person on request Here2Assist enrollment form
- Co-pay help for commercial insurance, as little as $0 per prescription for eligible patients 18 and older, not for Medicare, Medicaid, TRICARE, VA, DoD or state programs MIMRYLO Patient Support
- The Takeda Oncology Patient Assistance Program, Mimrylo at no cost for eligible people who are uninsured or whose plan does not cover it, after an application Here2Assist financial help
- A Bridge Program, Mimrylo at no cost for up to 2 months during a temporary gap in commercial coverage, for people already taking it
- Shipping from a specialty pharmacy, or pickup at the doctor's office where in-office dispensing is available, plus optional text updates and refill reminders
- Nurse Navigator check-ins every 8 weeks after enrollment Here2Assist FAQ
Details as the drugmaker publishes them. Here2Assist
Five questions for the pharmacist or the support line
- Which specialty pharmacy are you, and what number will the delivery call come from?
- How many cartons come in each shipment, and how many days ahead should I ask for the next one?
- If my hematologist raises my dose, will the new strength arrive before my next injection day?
- The Instructions for Use list some supplies that are not in the carton. Which ones are you sending, and do I need a sharps container?
- What cap color should my vial have at my current dose?
Questions people ask in the first weeks
How long does it take to get Mimrylo after it is prescribed?
There is no fixed number of days between the prescription and the first dose. Takeda says the benefits check is done within 1 business day of enrollment, but the prior authorization takes as long as the plan takes. Injection training also needs to happen before the first dose.
Do I inject Mimrylo myself?
Yes, you or a caregiver give it at home once you have been shown how. The label says a healthcare provider should teach you before treatment starts, and Here2Assist offers free nurse-led training. The outer upper arm is used only when a caregiver gives the injection.
How often are blood tests needed on Mimrylo?
The label calls for a complete blood count every 2 to 4 weeks after starting and during dose changes, or as the hematologist decides. The counts guide the dose toward a hematocrit below 45% and watch for rising platelets.
What if I miss a dose of Mimrylo?
On once-weekly dosing, inject it as soon as you remember. If it was more than 4 days late, the next injection comes 3 days later, then the usual schedule resumes. Twice-weekly dosing has different rules, and the label says to call your healthcare provider if you are unsure.
Does Mimrylo need to be refrigerated?
The label says to store Mimrylo at room temperature, 68 to 77 degrees Fahrenheit, in its original carton. It should not be frozen, and once mixed it must be injected within 4 hours.
Does Mimrylo have a boxed warning or a REMS?
Neither one applies to Mimrylo under its first label, revised in August 2026. The label has no boxed warning and no contraindications, and the FDA's approval letter does not require a REMS.
Why was Mimrylo denied by my insurance?
We found no public insurer policy for Mimrylo as of November 9, 2026, so each plan sets its own rules. A Here2Assist Nurse Navigator can explain what your plan asks for. Takeda offers the office sample letters of medical necessity and appeal.
Free email alert
Hear when the Mimrylo label changes
One email the day the FDA revises the Mimrylo label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Mimrylo only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Polycythemia vera for new trials, FDA decisions and label changes for every treatment.
Sources
- MIMRYLO (rusfertide) for injection, for subcutaneous use, prescribing information, Patient Information and Instructions for Use, Revised 8/2026, Takeda Pharmaceuticals America, via DailyMed and openFDA, August 28, 2026.
- NDA 220605 approval letter, Mimrylo (rusfertide) for injection, FDA, August 28, 2026.
- Drugs@FDA: New Drug Application (NDA) 220605, MIMRYLO, FDA, November 9, 2026.
- SPL history, MIMRYLO (RUSFERTIDE) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.], U.S. National Library of Medicine, DailyMed, November 4, 2026.
- MIMRYLO™ Patient Support Program, Takeda, November 9, 2026.
- MIMRYLO™ (rusfertide) Getting Started │ Takeda Oncology Here2Assist®, Takeda, November 9, 2026.
- MIMRYLO™ (rusfertide) Financial Assistance │ Takeda Oncology Here2Assist®, Takeda, November 9, 2026.
- MIMRYLO™ (rusfertide) FAQ │ Takeda Oncology Here2Assist®, Takeda, November 9, 2026.
- MIMRYLO™ (rusfertide) HCP Understanding Coverage │ Takeda Oncology Here2Assist®, Takeda, November 9, 2026.
- MIMRYLO™ (rusfertide) HCP Distribution and Fulfillment │ Takeda Oncology Here2Assist®, Takeda, November 9, 2026.
- MIMRYLO (rusfertide) Takeda Oncology Here2Assist Enrollment Form, 08/26 US-RUS-0191, Takeda, November 9, 2026.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing hematologist. Found an error? Use the report link in the footer and it will be checked against the source.